首页> 外文期刊>Journal of neuromuscular diseases. >Panel-Based Exome Sequencing for Neuromuscular Disorders as a Diagnostic Service
【24h】

Panel-Based Exome Sequencing for Neuromuscular Disorders as a Diagnostic Service

机译:基于面板的外核紊乱作为诊断服务的神经肌肉疾病测序

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Neuromuscular disorders (NMDs) are clinically and genetically heterogeneous. Accurate molecular genetic diagnosis can improve clinical management, provides appropriate genetic counseling and testing of relatives, and allows potential therapeutic trials. Objective: To establish the clinical utility of panel-based whole exome sequencing (WES) in NMDs in a population with children and adults with various neuromuscular symptoms. Methods: Clinical exome sequencing, followed by diagnostic interpretation of variants in genes associated with NMDs, was performed in a cohort of 396 patients suspected of having a genetic cause with a variable age of onset, neuromuscular phenotype, and inheritance pattern. Many had previously undergone targeted gene testing without results. Results: Disease-causing variants were identified in 75/396 patients (19%), with variants in the three COL6 -genes (COL6A1, COL6A2 and COL6A3 ) as the most common cause of the identified muscle disorder, followed by variants in the RYR1 gene. Together, these four genes account for almost 25% of cases in whom a definite genetic cause was identified. Furthermore, likely pathogenic variants and/or variants of uncertain significance were identified in 95 of the patients (24%), in whom functional and/or segregation analysis should be used to confirm or reject the pathogenicity. In 18% of the cases with a disease-causing variant of which we received additional clinical information, we identified a genetic cause in genes of which the associated phenotypes did not match that of the patients. Hence, the advantage of panel-based WES is its unbiased approach. Conclusion: Whole exome sequencing, followed by filtering for NMD genes, offers an unbiased approach for the genetic diagnostics of NMD patients. This approach could be used as a first-tier test in neuromuscular disorders with a high suspicion of a genetic cause. With uncertain results, functional testing and segregation analysis are needed to complete the evidence.
机译:背景:神经肌肉障碍(NMDS)是临床和遗传性的。准确的分子遗传诊断可以改善临床管理,提供适当的遗传咨询和检测亲属,并允许潜在的治疗试验。目的:建立与各种神经肌肉症状的儿童和成人纳米人群中核心小组的整体exome测序(WES)的临床用途。方法:临床外壳测序,其次是与核磁共弊相关的基因的诊断解释,在涉嫌发生遗传原因的396名患者的群组中进行,具有可变年龄,神经肌肉表型和遗传模式。许多人以前经过有针对性的基因测试而没有结果。结果:在75/396名患者(19%)中鉴定了致病变体,其中三个COL6 -GENES(COL6A1,COL6A2和COL6A3)中的变体作为所发现的肌疾病的最常见原因,其次是RYR1中的变体基因。这四种基因在一起占鉴定了明确遗传原因的案件的近25%。此外,可能在95例患者(24%)中发现了不确定意义的病原变体和/或变体,其中官能和/或分离分析应用于确认或拒绝致病性。在18%的病例中,患有疾病的疾病变异,我们接受了额外的临床信息,我们鉴定了相关的表型与患者的基因的遗传原因。因此,基于面板的WES的优点是其无偏见的方法。结论:整个外壳测序,随后过滤NMD基因,为NMD患者的遗传诊断提供了无偏见的方法。这种方法可以用作神经肌肉障碍中的第一层测试,具有高遗传原因的怀疑。通过不确定的结果,需要功能性测试和分离分析来完成证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号